-
Company Insights
Innovation and Patenting activity of Indivior Plc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Indivior Plc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Alcohol Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Alcohol Addiction - Drugs In Development, 2023’, provides an overview of the Alcohol Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Opium (Opioid) Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium (Opioid) Addiction - Drugs In Development, 2023’, provides an overview of the Opium (Opioid) Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Naltrexone Hydrochloride in Alcohol Dependence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naltrexone Hydrochloride in Alcohol Dependence report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naltrexone Hydrochloride in Alcohol Dependence Drug Details: Naltrexone hydrochloride (OPNT-002) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Buprenorphine SR in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Buprenorphine SR in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Buprenorphine SR in Pain Drug Details: Buprenorphine depot formulation (ALA-1000) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Buprenorphine SR in Opium (Opioid) Addiction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Buprenorphine SR in Opium (Opioid) Addiction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Buprenorphine SR in Opium (Opioid) Addiction Drug Details: Buprenorphine depot...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Latanoprost in Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Latanoprost in Glaucoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Latanoprost in Glaucoma Drug Details:Latanoprost is under development for the treatment of glaucoma. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naltrexone Hydrochloride in Alcohol Addiction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naltrexone Hydrochloride in Alcohol Addiction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Naltrexone Hydrochloride in Alcohol AddictionDrug Details:Naltrexone hydrochloride (OPNT-002) is under development for...
-
Company Profile
Indivior Plc – Company Profile
Indivior Plc (Indivior) develops and markets medicines for the treatment of opioid addiction. The company offers suboxone a monthly depot, and only approved film treatment for opioid dependence, subutex, a mono-buprenorphine sublingual tablet, sublocad injection, and nalscue for opioid use disorder, and perseris for schizophrenia. Its pipeline portfolio encompasses buprenorphine-based products, including INDV-1000 in pre-clinical phase and INDV-2000 in Phase I for substance use disorder, and AEF0117 in Phase II for treatment of cannabis disorder. Indivior offers products in the...
Add to Basket -
Company Profile
Addex Therapeutics Ltd – Company Profile
Addex Therapeutics Ltd (Addex) is a clinical-stage pharmaceutical company that discovers, develops and commercializes small-molecule pharmaceutical products, including allosteric modulators for neurological disorders. The company develops its proprietary clinical and preclinical-stage drug candidates using its allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) intended to treat Parkinson's disease levodopa-induced dyskinesia. It also carries out clinical and preclinical programs for various indications such as dystonia, epilepsy, post-traumatic stress disorder, Schizophrenia, Other Psychosis, addiction,...
Add to Basket